Health Care & Life Sciences » Biotechnology | Bellicum Pharmaceuticals Inc.

Bellicum Pharmaceuticals Inc.

Bellicum Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.33
Market Cap
$80.98 M
Shares Outstanding
46.01 M
Public Float
39.9 M

Profile

Address
Life Science Plaza
Houston Texas 77030
United States
Employees -
Website http://www.bellicum.com
Updated 07/08/2019
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M.

Financials

View All
Created with Highcharts 5.0.14Bellicum Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.7 9687 96883 96483 96448 54848 54869 24169 24191 77991 77998 03698 036201320142015201620172018025k50k75k100k125k
Created with Highcharts 5.0.14Bellicum Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.001 7801 7802822823883881851851 1201 1202013201420152016201720180500100015002000

Richard A. Fair
President, Chief Executive & Financial Officer
James Farrell Brown
Chairman